Form 4: Aadi Bioscience Director Richard E. Maroun Acquires Stock Options

Director Richard E. Maroun acquired stock options in Aadi Bioscience, Inc. on June 12, 2024.

Summary

• Richard E. Maroun, a director of Aadi Bioscience, Inc., acquired stock options on June 12, 2024.
• The stock options grant the right to buy 45,832 shares of common stock at an exercise price of $1.70.
• The options vest on the earlier of June 12, 2025, or the day before the next annual meeting of stockholders, contingent upon Maroun's continued service as a Service Provider.
• Following the transaction, Maroun directly owns 45,832 derivative securities.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating confidence in the company's future. The sentiment is neutral to positive.

Positives

• The acquisition of stock options by a director signals confidence in the company's future performance.
• The vesting schedule incentivizes the director to remain with the company.

Future Outlook

The vesting of the stock options is contingent upon the director's continued service, aligning their interests with the company's long-term success.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotech industry.
• The vesting schedule of one year is fairly standard, aligning with typical industry practices for incentivizing long-term performance.
• Comparable companies like Mirati Therapeutics or Relay Therapeutics also utilize stock options as part of their executive compensation plans.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, incentivizing value creation.
• Employees may view the grant as a positive sign of the company's commitment to its leadership.

Key Dates